On August 26, 2025, Pulse Biosciences, Inc. announced early findings from a clinical study showing that their CellFX system resulted in up to a 93% reduction in size of benign thyroid nodules after one year, with significant symptom relief. The study was conducted in Naples, Italy, and demonstrated no fibrosis or scarring on follow-up ultrasounds.